Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan-Mar;36(1):104-109.
doi: 10.4103/joacp.JOACP_3_19. Epub 2020 Feb 18.

Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention

Shuchita Garg  1 , Malti Vij  2 , Neeraj Edward  1 , Brinder Vij  3
Affiliations

Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention

Shuchita Garg et al. J Anaesthesiol Clin Pharmacol. 2020 Jan-Mar.

Abstract

Headaches and migraines continue to be a leading cause of suffering and disability. As per the Global Burden of Disease Survey conducted in 2010, the exact magnitude of the disease still is underestimated. Migraine alone continues to rank seventh as a cause of disability. Various therapeutic modalities exist and newer classes of medications are currently being trialed to provide effective treatment to this population of patients. Erenumab, a calcitonin gene-related peptide receptor inhibitor, is a recent addition to this armamentarium and has been approved by the FDA for use in 2018. It has shown modestly improved outcomes according to the current trials. However, long-term outcomes and adverse effects still are under research. The following article elaborates on the current literature and evidence on this novel drug.

Keywords: Calcitonin gene-related peptide receptor antagonist; Erenumab; migraine.

PubMed Disclaimer

Conflict of interest statement

Dr. Brinder Vij is on advisory board of Amgen and is on speaker Bureau as well for Aimovig with Amgen Pharmaceuticals.

Figures

Figure 1
Figure 1
Mechanism of Action of Erenumab
Figure 2
Figure 2
Erenumab competitively blocks the CGRP receptor thereby antagonizing the CGRP receptor functions
See this image and copyright information in PMC

References

    1. Headache Classification Committee of the International Headache Society (IHS) The International classification of headache disorders, 3rd edition (beta version) Cephalalgia. 2013;33:629–808. - PubMed
    1. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: The seventh disabler. J Headache Pain. 2013;14:1. - PMC - PubMed
    1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–602. - PMC - PubMed
    1. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16:877–97. - PMC - PubMed
    1. Ray BK, Paul N, Hazra A, Das S, Ghosal MK, Misra AK, et al. Prevalence, burden, and risk factors of migraine: A community-based study from Eastern India. Neurol India. 2017;65:1280–8. - PubMed